Revolution Medicines' drug daraxonrasib doubled survival time in a Phase 3 trial for pancreatic cancer, reducing death risk by 60% compared to chemotherapy.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
76% tumor shrinkage
6.5 Months survival increase
60% risk of death reduced